Jul 15, 2020
July 2020 By M.Angeles Montero, BTOG Steering Committee Member From 2011 and updated in 2015, the identification of therapeutic targets for the treatment of lung cancer has resulted in the new WHO classification system for non-resection specimens, small biopsies and...
Feb 24, 2020
February 2020 By Dr Adam Januszewski, Higher Specialty Trainee in Medical Oncology and Honorary Clinical Fellow, Imperial College London On application to medical school, lifelong learning is what I signed up to. Although at that point I wasn’t entirely sure what it...
Feb 7, 2020
February 2020 By Dr Antonia Field-Smith, Consultant in Palliative Medicine, West Middlesex University Hospital Despite all the recent successes with immunotherapy, I am well aware that lung cancer remains the most common cause of cancer death in the UK. The patients...
Feb 7, 2020
February 2020 By Dr Helen McDill, Respiratory Registrar and Interventional Respiratory Fellow, Derriford Hospital, Plymouth NHS Trust What a fantastic 3 days at BTOG 2020 – I have returned back to work full of ideas and enthusiasm about how to improve our lung...
Nov 18, 2019
November 2019 By Tom Newsom-Davis, BTOG Vice-Chair 1st Line Combination Immunotherapy for NSCLC: Checkmate-227 Further results from the Checkmate-227 trial were presented at ESMO 2019. Checkmate-227 is a study with multiple treatment arms, which has released results...
Nov 15, 2019
November 2019 By Tom Newsom-Davis, BTOG Vice-Chair 1st Line Osimertinib Overall Survival Results: FLAURA The overall survival (OS) date from the FLAURA study was presented at the Presidential Session of ESMO 2019, following publication of the Progression Free Survival...
